Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12911102 | 0.82 | P2RX7 (0.42) | KDM5AGSK3BDYRK1ASMYD3NTRK1 | |
| SCHEMBL17518681 | 0.82 | GSK3B (0.42) | KDM5AGSK3BDYRK1ASMYD3NTRK1 | |
| SCHEMBL26605437 | 0.82 | GSK3B (0.40) | KDM5AGSK3BDYRK1ASMYD3NTRK1 | |
| SCHEMBL12443623 | 0.79 | CNR1 (0.40) | KDM5AGSK3BDYRK1ASMYD3NTRK1 | |
| SCHEMBL3266560 | 0.79 | GRM2 (0.42) | KDM5AGSK3BDYRK1ASMYD3KCNA3 | |
| SCHEMBL2757975 | 0.79 | CNR1 (0.40) | KDM5AGSK3BDYRK1ASMYD3CNR1 | |
| SCHEMBL24253400 | 0.78 | KCNA3 (0.41) | KDM5AGSK3BDYRK1ASMYD3NTRK1 | |
| SCHEMBL1614140 | 0.77 | — | — | |
| SCHEMBL170374 | 0.77 | — | — | |
| SCHEMBL14704051 | 0.77 | NTRK1 (0.38) | KDM5AGSK3BDYRK1ASMYD3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230219970-A1 | DIHYDROCHROMENE DERIVATIVES | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-13 | — | — | US | disclosed |
| US-11639357-B2 | Dihydrochromene derivatives | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-02 | — | — | US | disclosed |
| US-20210002290-A1 | DIHYDROCHROMENE DERIVATIVES | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-01-07 | — | — | US | disclosed |
| US-10807993-B2 | Dihydrochromene derivatives | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20200216461-A1 | DIHYDROCHROMENE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-09 | — | — | US | disclosed |
| US-9505767-B2 | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | disclosed |
| US-8865720-B2 | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-21 | — | — | US | disclosed |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-06 | — | — | US | disclosed |
| US-7704998-B2 | anticancer agents; catalytic hydrogenation | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1485365-B1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-14 | — | — | EP | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | VAN EMELEN KRISTOF | 2008-05-08 | — | — | US | disclosed |
| WO-2008047883-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | WO | disclosed |
| US-7319148-B2 | Combinatorial production of nucleotide and nucleoside (XiTP) analogues | INSTITUT PASTEUR (FR) | 2008-01-15 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | EMELEN KRISTOF V | 2007-06-21 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
| US-7205304-B2 | medicine to inhibit proliferative conditions, such as cancer and psoriasis | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216461-A1 | DIHYDROCHROMENE DERIVATIVE | H1-3, H1-2, TPD52L2 | BAZ2B 725/4885KDM5A 1660/4885GSK3B 2855/4885 |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM5A, KDM5B, KDM5C | BAZ2B 91/4885KDM5A 1/4885GSK3B 820/4885 |
| US-20140038979-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | BAZ2B 77/4885KDM5A 68/4885GSK3B 1004/4885 |
| US-20210002290-A1 | DIHYDROCHROMENE DERIVATIVES | H1-3, H1-2, H1-0 | BAZ2B 765/4885KDM5A 1662/4885GSK3B 2879/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | BAZ2B 3819/4885KDM5A 3540/4885GSK3B 513/4885 |
| US-11639357-B2 | Dihydrochromene derivatives | H1-3, H1-2, H1-0 | BAZ2B 765/4885KDM5A 1662/4885GSK3B 2879/4885 |
| US-20230219970-A1 | DIHYDROCHROMENE DERIVATIVES | H1-3, H1-2, H1-0 | BAZ2B 765/4885KDM5A 1662/4885GSK3B 2879/4885 |
| US-10807993-B2 | Dihydrochromene derivatives | H1-3, H1-2, H1-0 | BAZ2B 765/4885KDM5A 1662/4885GSK3B 2879/4885 |
| US-20070142393-A1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC3, HDAC1, HDAC11 | BAZ2B 77/4885KDM5A 68/4885GSK3B 1004/4885 |
| US-20080108601-A1 | anticancer agents; catalytic hydrogenation | HDAC1, HDAC11, HDAC3 | BAZ2B 72/4885KDM5A 208/4885GSK3B 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.